Anvisa approves new treatment for advanced cancer in Brazil
Anvisa (National Health Surveillance Agency) approved TECARTUS® (brexucabtagene autoleucel), a gene therapy drug developed by the Kite laboratory, to treat hematologic cancer.
Indicated for adults, TECARTUS® is the first therapeutic advance for this rare type of cancer in the country.
ontact your local ELS consultant or via email info@elssolutions.pt
ELS Group brings together a team of highly specialized professionals with proven experience in regulatory frameworks and compliance in the pharmaceutical field.
Rely on experts to support your regulatory decisions and accelerate the growth of your products safely and efficiently.
Experts in pharmaceutical consulting, regulatory strategy, and market access to support your company with safety, compliance, and efficiency. Talk to a consultant.
